See the DrugPatentWatch profile for cosentyx

Cosentyx (secukinumab) is a medication used to treat various conditions such as plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis [1]. It is a type of drug known as a monoclonal antibody, which works by targeting and blocking a specific protein in the body called interleukin-17A (IL-17A) [1].

According to the drug's prescribing information, there are no specific studies that have been conducted to evaluate the effect of Cosentyx on the immune response to vaccines [2]. However, it is generally recommended that live vaccines should be avoided in patients receiving immunosuppressive therapy, including Cosentyx [2]. This is because these types of vaccines, such as the measles, mumps, and rubella (MMR) vaccine or the varicella (chickenpox) vaccine, contain live, weakened forms of the virus, and there is a risk that the immune system may not be able to effectively fight off the virus, leading to infection [3].

It is important to note that the immune system plays a crucial role in the body's response to vaccines. Vaccines work by exposing the immune system to a small, harmless piece of a virus or bacteria, which triggers the immune system to produce antibodies to fight off the infection [3]. If a person's immune system is suppressed, it may not be able to produce an adequate response to the vaccine, which could reduce the vaccine's effectiveness [3].

In summary, while there is limited information specifically regarding the effect of Cosentyx on the body's response to vaccines, it is generally recommended that live vaccines should be avoided in patients receiving immunosuppressive therapy, including Cosentyx. It is always best to consult with a healthcare provider for specific guidance on vaccinations while taking Cosentyx.

Sources:

* [1] Cosentyx (secukinumab) [Prescribing Information]. Novartis Pharmaceuticals Corporation; 2021. <https://www.novartis.us/sites/www.novartis.us/files/cosentyx.pdf>.
* [2] Cosentyx (secukinumab) [Highlights of Prescribing Information]. Novartis Pharmaceuticals Corporation; 2021. <https://www.novartis.us/sites/www.novartis.us/files/cosentyx.pdf>.
* [3] Centers for Disease Control and Prevention. Vaccine Information for Persons with Weakened Immune Systems. <https://www.cdc.gov/vaccines/adults/rec-vac/people-with-weakened-immune-systems.html>.
* DrugPatentWatch.com - Secukinumab. <https://www.drugpatentwatch.com/drugs/secukinumab>.